What is FIND ?
FIND
mission
Promote the development and early implementation of innovative diagnostic tests that contribute significantly to patient care and disease management in resource-poor environments.
FIND Initiatives
1. By developing diagnostic tests, we will realize a medical and health system that can provide appropriate treatment to patients and invest resources where they are needed.
2 .Accelerate the deployment of diagnostics through project management: ISO13485 certification for project management and clinical trials
3. Earn preferential prices for investment
4. Strengthen local lab facilities and make new technologies available to everyone.
Achievements of FIND
1.tuberculosis
Introducing 6 new technologies
・40% improvement in case detection rate, shortened time to treatment decision for multidrug-resistant tuberculosis from months to hours
・Save up to 300,000 people a year
Adopted in 25 highly epidemic countries due to national policy changes
・Detected 25,000 cases of multidrug-resistant tuberculosis in 2012 alone: Education and training for more than 2,000 staff at more than 80 new laboratories
2.Malaria & Acute Febrile Syndrome
Quality evaluation of rapid diagnostic test by FIND / WHO
・Fourx more than rapid diagnostic tests: Low quality product percentage dropped from 76% to 17%
・Efforts to respond to 85% of misdiagnosis and treatment, and to reduce drug-resistant cases
LAMP method: potential as a tool for disease elimination, currently used for mass screening in the first three countries
Blood Transfer Device: Estimated 50 million units sold in 2012
3.African Trypanosomasis & Neglected Diseases
Introducing two new technologies for the first-ever rapid diagnostic test for the definitive diagnosis of African trypanosomiasis
Successful support programs in 11 endemic countries in Africa
FIND technology will be adopted in a country-led African Trypanosomiasis Elimination Campaign.
Consultant
Research & Innovation Japan Inc.
Consultation in biotech and in vitro diagnostic business
What is the outline of RIJ’s consultant business?
RIJ is a consulting company for biotechnology and in vitro diagnostics. RIJ prepares the launch pad for foreign companies to introduce their products in the Japanese market. The main activity of RIJ is to offer consulting services to foreign companies
who want to bring their products with a unique technology to Japan. RIJ advises the companies on the modalities of the Japanese market and assist in the promotion, marketing and distribution of the foreign company’s products in Japan.
How does RIJ make leverage on this consulting business?
The market in Japan comprises of small-, medium-and large-scale manufacturers of diagnostics and biotechnology products. Japan is also filled
with wholesalers who distribute the products to the end-users. RIJ’s role is to act as a bridge between the manufacturer and wholesaler. In addition, RIJ advises local manufacturers who wish to expand their technology to overseas market. It is RIJ’s responsibility to identify the right distributor both within and outside the boundaries of Japan (please see attached article).
Mr. K.Hirasawa, CEO of RIJ was in Boehringer Mannheim kk and Roche Diagnostic Inc for 25 years totally. And he is now a Business Adviser of Foundation Innovative New Diagnostics(FIND) in Japan.
Please contact us. RIJ will help your firm to find appropriate marketing partner to make your business successfully in Japan.
downlord (200KB)
Products handled by
Research & Innovation Japan Inc.
iNtRON Biotechnology
[RUO] LiliF™ GBN COVID-19 Ag Rapid Kit is a lateral flow chromatographic immunoassay for the detection of SARS-CoV-2 specific antigens in human nasopharyngeal swab specimens.
It is intended to be used by professionals as an aid in the diagnosis of infection with SARS-CoV-2 coronavirus, which causes COVID-19 disease.
After applying the extracted swab specimen onto the hole of testing device, human’s sample first react with gold conjugated mouse monoclonal antibody to SARS-CoV-2 Nucelcapsid antibody and rabbit anti-chicken IgY antibody.
After that, each reactant diffuses on the membrane to the another monoclonal antibody to SARS-CoV-2 Nucelcapsid antibody marked as test lines and the control line is coated with chicken IgY antibody.
If positive, the test line turns to red color because antigen-antibody-gold conjugate complex is formed on the test lines. The control line is intended for procedural control and should always appear if the test procedure is performed correctly and the control line reagents are operated.
[RUO] LiliF ™ Streptococcus pneumoniae Ag Rapid Kit is a research kit that qualitatively detects the pneumococcal antigen (C-polysaccharide) in a sample using the ImmunoChromatographic Assay.
altona Diagnostics
The RealStar® SARS-CoV-2 RT-PCR Kit 1.0 is a reagent system, based on real-time PCR technology, for the qualitative detection of lineage B-betacoronavirus (B-βCoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific RNA. SARS-CoV-2, formerly known as 2019-nCoV, is the causative agent of the coronavirus disease 2019 (COVID-19).
FORA
For blood glucose measurement in experimental animals
Introducing Lab Gluco, a quick and easy measuring device
・Palm-sized simple measuring device
・Measurement time is only 5 seconds
・Required sample volume is only 1.1 μL
・Sensor that is easy to handle
・Hygienic disposal with injector
・Accurate measurement with a wide range of hematocrit tolerance
Asuragen
AmplideX PCR/CE FMR1 Reagents* are market-leading research tools for the detection of CGG repeats in the fragile X mental retardation (FMR1) gene.
These reagents provide a PCR-only approach based on Triplet Repeat Primed PCR (TP-PCR) design to reliably amplify and detect all alleles including Full Mutations.
Features & Benefits
AmplideX PCR/CE FMR1 Reagents* have created an easy-to-use, accessible, high performance method for laboratories to reliably analyze CGG repeats and detect interrupting AGG sequences in the FMR1 gene.
Reduced Complexity
Ease-of-analysis of the FMR1 gene has been simplified through:
・Implementation of proprietary PCR solution for amplifying GC-rich regions
・Automation of result calling using AmplideX PCR/CE FMR1 Analysis Module
Optimized Workflow
Valuable operator hands-on time has been significantly reduced through:
・Direct injection of PCR products (no PCR clean up) in to Capillary Electrophoresis platforms
・Decreased need for Southern blot analysis (up to 50 fold)
・End-to-end solution for FMR1 analysis including all necessary reagents and software
Quality Performance
Performing FMR1 Analysis with Greater Sensitivity and Accuracy:
・Detection of all allele expansions, including low abundance full mutation size mosaics with up to at least 1300 CGG repeats
・Up to 875 fold more sensitive than Southern blot1
・Resolution of female homozygous and heterozygous samples and indication of interrupting AGG sequences
・Proven performance as indicated by more than 30 peer reviewed publications
*For Research Use Only. Not for use in diagnostic procedures.
LogTag
TRIX-8
MULTI-USE TEMPERATURE LOGGER
・WHO PQS Pre-qualified under E06/06: PQS CODE E006/00.
・Versatile, wide range, multi-trip Temperature Logger.
・8000 readings memory capacity with up to 3 years battery life.
・‘OK’ & ‘ALERT’ Indicator with high and low customizable alarms.
・Industry best download time – less than 5 seconds for full memory.
The LogTag® TRIX-8 is a versatile, wide range, multi-trip Temperature Logger, featuring high-resolution temperature readings over a measurement range of -40°C to +85°C (-40°F to +185°F). Enclosed in a robust and durable polycarbonate case, the TRIX-8 features a real-time clock, which provides date/time stamps for each temperature reading.
Using the LogTag® Interface and the freely available companion software LogTag Analyzer, the LogTag® is easily set-up for recording conditions including delayed start, sampling interval, number of readings, continuous or fixed number of readings and configuration of conditions to activate the ALERT indicator.
Readings are downloaded using LogTag® Analyzer, which provides facilities for charting, zooming, listing data statistics and allows exporting the data to other applications such as Excel.
The LogTag® TRIX-8 complies with the relevant international standards for temperature monitoring devices, such as FCC, CE, C-TICK, TÜV, EN12830, WHO PQS and RoHS.
This not only demonstrates the quality of the LogTag® TRIX-8, but underlines its suitability for temperature monitoring applications where accuracy and consistency are required.
Microsynth : The Swiss DNA Company
Microsynth (founded in 1989) is a leading European company in the area of nucleic acid synthesis & analysis. The main activities are divided into following three business areas:
1.DNA/RNA Synthesis
2.DNA/RNA Analysis and Sequencing
3.Contract Research/Outsourcing
For almost three decades, the companys' objective has been to serve its customers by delivering products and services of the highest quality, on time and with outstanding service – and all this at competitive prices.
URL: Microsynth Site